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1.Introduction 
1.1 Definition1 
 Suspension are heterogenous system containing of two phases the 
continuous or external phase is generally a liquid or semisolid, and the 
dispersed or internal phase in made  up of matter that is essentially 
insoluble in, but dispersed throughout, the continuous phase: The 
insoluble matter may be intended for physiological absorption or for 
internal or external coating function. The disperse phase may consist of 
discrete particles, or it may be a network of particles resulting from 
particle – particle interactions. 
1.2  PHARMACEUTICAL APPLICATIONS OF SUSPENSION2 
 Suspensions can be used as oral dosage forms, applied topically to 
the skin or mucous membrane surfaces, or given parentarally by injection. 
Suspension as oral drug delivery systems: 
Many People have difficulty in swallowing solid dosage forms and 
therefore require the drug to be dispersed in a liquid. 
 Some materials are required to be present in the gastro intestinal 
tract in a finely divided form, and their formulation, a suspension will 
provide the desired high surface area. Solid such as kaolin, Magnesium 
Carbonate and Magnesium Trisilicate are used for the adsorption of 
toxins, or to neutralize excess acidity. A dispersion of finely divided 
silica in dimethicone 1000 is used in veterinary practice for the treatment 
of ‘Forthy bloat’. The taste of most drug is more noticeable if it is in 
solution rather than in an insoluble form. 
Suspension for topical administration 
Suspension of drugs can also be formulated for topical application. 
They can be fluid preparations, such as calamine lotion, which are 
designed to leave a light deposit of the active agent on the skin after quick 
evaporation of the dispersion medium. Some suspension, such as pastes, 
are semisolid in consistency and contain high concentration of powders 
dispersed usually in a paraffin base. It may also be possible to suspend a 
powered drug in an emulsion base, as in zinc cream. 
Suspension for parenteral use and inhalation therapy: 
 Suspension can also be formulated for parenteral administration in 
order to control the rate of absorption of drug, by varying the size of the 
dispersed particles of active agent, the duration of activity can be 
controlled, the  absorption rate of the drug into the blood stream will then 
depend simply in its rate of dissolution. If the drug is suspended in a fixed 
oil such as arachis or sesame, the product will remain after injection in 
the form of an oil globule, thereby presenting to the tissue fluid a small 
surface area from which the partitioning of drug can occur. The release of 
drug suspended in the aqueous vehicle will be faster, as some diffusion of 
the product will occur along muscle fibers and become miscible with 
tissue fluid. This will present a larger surface area from which the drug 
can be released. 
 The adsorptive properties of fine powders are also used in the 
formulation of some inhalation the volatile components of menthol and 
eucalyptus oil would be lost from solution vary rapidly during use, 
whereas a more prolonged release obtained if the two active agents are 
adsorbed on to light magnesium carbonate prior to the preparation of a 
suspension. 
1.3 FLOCCULATED AND DEFLLOCULATED SYSTEMS3: 
 Having incorporated a suitable wetting agent, it is then necessary to 
determine whether the suspension is flocculated or deflocculated and to 
decide which state is preferable whether or not a suspension flocculated 
or deflocculated depends on the relative magnitude of the forces of 
repulsion and attraction between the particles. The effect of these particle 
– Particle interaction have been adequately covered. 
 In a deflocculated system the dispersed particles remain as discrete 
units and, because the rate of sedimentation depends on the size of each 
unit, settling will be slow. The supernatant of a deflocculated system will 
continue to remain cloudy for an appreciable time after shaking, due to 
the very slow settling rate of the smallest particles in the product, even 
after the larger ones have sedimented. The repulsive forces between 
individual particles allow them to slip fast each other as they sediment. 
The slow rate of settling prevent the entrapment of liquid within the 
sediment. Which thus becomes compacted and can be very difficult to 
redisperse. This phenomenon is also called caking or claying, and is the 
most serious of all the physical stability problem encountered in 
suspension formulation. 
 The aggregation of particles in a flocculated system will lead to a 
much more rapid rate of sediemention or subsidence because each unit is 
composed of many individual particles and is therefore larger. The rate of 
settling will also depend on the porosity of the aggregate, because if it is 
porous the dispersion medium can flow through, as well as around each 
aggregate or flocculated as it sediments. 
 In a flocculated system the supernatant quickly becomes clear, as 
the larger flocs that settles rapidly are composed of particles of all size 
range the appearance of both flocculated and deflocculated suspension at 
given time after shaking. 
 In summary, deflocculated systems have the advantage of a slow 
sedimentation rate, there by enabling a uniform dose to be taken from the 
container, but when settling, does occurs the sediment is compacted and 
difficult to redisperse. Flocculated systems form loose sediments which 
are easily redispersible but the sedimentation rate is fast and there is a 
danger of an in accurate dose being administered also the product will 
look inelegant. 
 Controlled flocculation: 
 A deflocculated system with a sufficiently high viscosity to prevent 
sedimentation would be an ideal formulation. It can not be guaranteed, 
however, that the system would remain homogenous during the entire 
shelf – life of the product usually a compromise is reached in which the 
suspension is partially flocculated to enable adequate redispersion if 
necessary,and viscosity is controlled so that the sedimentation rate is at a 
minimum.  
 The next stage of the formulation process after the addition of the 
wetting agent is to ensure that the product exhibits the correct degree of 
flocculation. Under flocculated will give those undesirable properties that 
are associated with deflocculated systems. An over flocculated product 
will look inelegant and to minimize settling, the viscosity of the product 
may have to be so high that any necessary redispersion would be difficult 
controlled flocculated is usually achieved by a combination of particle 
size control the use of electrolytes to control zeta potential of the addition 
of polymer to enable cross linking to occur between particles. Some 
polymer have the advantage of becoming ionized in an aquous solutions 
and can therefore at both electro statically stearically. These materials are 
also termed poly electrolytes. 
1.4. RHEOLOGY OF SUSPENSIONS4:- 
 An ideal pharmaceutical suspension would exhibit a high apparent 
viscosity at low rates of shear so that on storage the suspended particles 
would either settle very slowly or preferably remain permanently  
suspended. At high rates of shear such as those caused by moderate 
shaking of the product the apparent viscosity should fall sufficiently for 
the product to be powered easily from its container. The product if for 
external use should then spread easily without excessive dragging, runs 
off the skin surface. If intended for injection the product should pass 
easily through a hypodermic needle with only moderate pressure applied 
to the syringe plunger it would then be important to be reformed after a 
short time to maintain adequate physical stability. 
 A flocculated system partly fulfils these criteria in such a system 
pseudo plastic behavior is exhibited as the structural progressively breaks 
down under shear. The product then shows the time dependent 
reversibility of this loss of structure which is termed thixotropy. 
 A deflocculated system however would exhibit Newtonian 
behavior owing to absence of such structures and may even if high 
concentration of disperse phase are present exhibit dilatancy. 
Although a flocculated system may exhibit some thixotropy and 
plasticity, unless a high concentration of disperse phase is present it may 
not be sufficient to prevent rapid settling particularly if a surfactant or an 
electrolyte is present as a flocculating agent in these cases suspending 
agents may be used to increase apparent viscosity of the system. 
 Suitable materials are the hydrophilic polymers discussed above. 
These exerts their effect by entrapping the solid dispersed particles within 
their gel like network so preventing sedimentation. At low concentration 
many suspending agents can be used to control flocculation and it must 
be realized that if large quantities are to be used to enhance viscosity the 
degree of flocculation may also be altered. 
 
1.5. CHARACTERISTICS OF ORAL AQUEOUS SUSPENSION  
Efficacy5:- 
 Drug suspension are often very effective pharmacologically and are 
less complicated to manufacture than other dosage forms. Their 
effectiveness may be attributed to a number of factors. For example, drug 
formulated as suspension are more bioavailable than tablets or capsules. 
Bioavailable versus the solid dosage formulation may also be enhanced 
by decreasing the particle size of the drug. 
 Suspensions are often more effective than tablets and capsules in 
the paediatric and geriatric patients. These patients generally find 
suspensions easier to swallow and also dose flexibility. 
Desired Attributes:- 
 Aqueous suspension are defined as systems of insoluble drug 
dispersed in a water vehicle. In addition to drug, a typical suspension may 
contain several other ingredients including wetting agent suspending 
agent, protective colloid, flocculating agent, sweetener,preservatives, 
buffer system, flavour, colour, sequestering agent and antifoaming agent. 
 
1.6. PRINCIPLES OF FORMULATION6 
Since the specific properties of various suspending drugs differ, no single 
procedure will always produce a successful suspension product. Different 
methods have been developed with varying degree of success. However 
certain principles have been recognized that are fundamental in all 
successful formulations. 
Particle size:- 
 It is an important consideration for the physical stability of the 
suspension. As the insoluble drug settles, a nonuniform distribution 
results. A major goal of the formulation is to slow or even prevent the 
sedimentation of the drug particles. The relationship of factors that 
describes the race of particles settling or sedimentation is stoke’s law. 
V = d2(P1 – P2) g/18 
Where, 
V = Sedimentation rate of average particle 
d = Mean Particle diameter 
P1 = Particle density 
P2 = Density of the dispersion medium 
g = acceleration due to gravity 
n = Viscosity of the dispersion medium 
The above equation illustrates that the sedimentation rate is directly 
proportional to the square of particle diameter and therefore small 
particles settle slower than longer settling. In addition particle – Particle 
interactions can also have a significant effect on suspension stability. 
For suspension with a relatively high percentage of solids interparticle 
interaction may produce more viscous or thixotropic dispersions smaller 
particles will have a high surface area/weight ratio that favours 
interactions between the particles and may produce desirable rheological 
characteristics. 
 In addition to the effects on the physical properties of a suspension 
particle size has important implications on the biopharmaceutical 
performance of the drug. For drugs whose solubility in water is slow, the 
dissolution rate of the drug particles may be primary factor that limits 
absorption of the drug. In these cases, the rate and extent of absorption of 
the drug may be enhanced, through the use of the particles of small 
diameter. Small particles dissolve faster than larger particles due to the 
increased surface area per unit weight of drug of the former. 
Some Drugs will pose problems  such as particle size reduction and 
polymorphism and crystal growth to formulation in most pharmaceutical 
suspensions the range of particle size reduction dry milling,  spray drying, 
micro pulverization and fluid energy grinder. 
 
Viscosity:- 
 Stokes law illustrates the inverse relationship between viscosity of 
the dispersion medium and rate of particle settling. An increase in 
viscosity produces a slower sedimentation rate and increase physical 
stability. Viscosity is also increased by the volume fraction of particles,  
the most common method of increasing viscosity is by adding a 
suspending agent. Too high a viscosity is undesirable, it interferes with 
pouring and redispersal of settled particles. 
 According to stoke’s law, sedimentation rate is also lowered by 
reducing the density difference between the particles and the dispersion 
medium. The control of sedimentation is important in maintaining the 
integrity of a dispersion system. Stokes law defines the sedimentation rate 
of sphere in a fluid as 
 Sr = 2ga2 (ds – dl) 9n 
 Where, 
 Sr = Sedimentation rate 
 ds = Density of sphere 
 dl = Density of liquid 
 a = Particle size  
 n = Viscosity of continuous phase. 
 Although most days in suspension are not perfect spheres and the 
suspension are not dilute enough to follow stoke’s law the equation is still 
useful. From the equation three methods of controlling sedimentation are  
i) Particle size reduction 
ii) Density matching 
iii) Viscosity building 
If the density of the medium and the suspended particles are same, 
sedimentation will not occur. The rheological characteristics of the 
polymer solutions used to sterilize disperse system are very important. 
 
 
Viscosity aging effects: 
 The shelf life of a dispersion depends on the chemical stability of 
its ingredients as well as the physical stability of the system. Several 
factors that may be responsible for changes in dispersion viscosity over a 
period of time. Some are obviously due to alteration with rest of the 
system. 
 Particle growth may be independent of polymer content, although 
polymers present may reduce the rate of change of particle size. 
Depolymerization results in a decrease in organization. Molecular weight, 
hence decrease in viscosity. 
 Depolymerization occurs while processing under high shear 
chemical changes in the system over time, producing a drift in pH or 
generating ionic products may alter viscosity. Polymers may introduce a 
second order effect on viscosity by acting as either flocculating or 
deflocculating agent. Because of variety of factors that an alter viscosity 
over times, some of which increase viscosity while others have opposite 
effect. Small drifts in apparent viscosity are often encountered however 
substantial changes are cause for concern because of changes in the 
resistance to sedimentation and also because they suggest that chemical 
or physical changes of some kind are taking place. 
 
Causes of change in viscosity in disporse system upon storage. 
Cause Usual effect on viscosity 
Depolymerization  Reduction  
Particle growth Reduction  
Slow polymer hydration Increase 
Chemical change dispersion  Variable  
Increase in flocculation Increase  
 
Wetting:- 
 Hydrophilic drugs are easily wetted by water or other polar liquids. 
They may also greatly increase the viscosity of water suspensions and 
are incorporated into suspensions without the use of wetting agents. 
Most drugs are hydrophobic and when suspended, frequently float on the 
vehicle surface due to poor wetting. 
 A wetting agent enhances the ability of the dispersion medium or 
suspension vehicle to spread on the surface of the drug particles by 
reducing the interfacial tension between solid particles and vehicles. 
Low concentrations of surfactants are commonly used. Excess 
concentrations may lead to foaming or unpleasant taste. 
 An addition caution with wetting agents is the increased possibility 
of caking, since the coated particles resists aggregate formation, settle 
individually and may form a dense sediment. 
Mixing:- 
 It is the major operation of suspension preparation. It is very 
important since inadequate mixing results in non homogeneity of the 
drug dispersed in the vehicle if the drug is hydrophobic, a wetting agent 
should be included. Sometimes shearing forces from ball mill or colloid 
mill are used to break up particles aggregates for better wetting and 
dispersion of drug. 
 The addition of suspending agent such as carboxymethyl cellulose 
to build viscosity increases the difficulty of mixing. The equipment 
must have the capacity to mix but the excessive shearing and its heat 
can fracture polymeric suspending agent and should be avoided often 
the completed suspension is passed through a colloid mill to break up 
excessive particle aggregates and to ensure adequate mixing of the 
final product. 
Flocculation:- 
 It is the process, in which the particles are allowed to come 
together and formation of loose particle aggregates. The floc settle and 
produce a sediment which is less dense and easier to resdisperse. If the 
flocculated particles have a sufficient concentration prior to settling, a 
continuous structure is produced which results in yield Value and little 
sedimentation. The yield value can be used as indicator for the extent 
of flocculation. 
 The material used to produce flocculation in suspension namely 
electrolytes, surfactants and polymers. Electrolytes act as a 
flocculating agent by reducing the electric barrier between the 
particles, as evidenced by a decrease in the zeta potential and the 
formation of a bridge between adjacent particles so as to link them 
together in a loosely arranged structure. 
 Surfactants both ionic and non-ionic, have been used to bring about 
flocculation of suspended particles. 
 Polymers are long-chain, high molecular-weight compounds 
containing active groups spaced along their length. These agent act as 
flocculating agents because part of the chain is adsorbed on the 
particle surface, with the remaining parts projecting out into the 
dispersion medium. Bridging between these latter portions leads to 
formulation of flocs. 
1.7 Commonly used   ingredients/Additives7:- 
 The term ‘additive’ refers to those components of a formulation 
which do not posses any therapeutic activities and which generally 
facilitate the stability, use or manufacture of a formula. These additive 
may have an effect in the physicochemical stability of the formulae 
and on the bioavailability of the drug. 
Suspending Agent:- 
 These agents are used to impart greater viscosity and retard 
sedimentation factors to consider during selection include suspending 
ability in the system, chemical compatibility with a all ingredients, 
especially the drug, length of time for hydration, appearance, source, 
reproducibility of these consideration from batch to batch and cost. 
 These agents subdivided in to cellulose derivatives, clays, natural 
gums, synthetic gums miscellaneous agents. 
Cellulose derivative:- 
 These derivatives are subdivided into cellulose, methylcellulose, 
ethyl cellulose and propyl cellulose group. These are semi synthetic 
have batch to batch reproducibility of their characteristic excluding 
sodium carboxy methyl cellulose, these are nonionic and their fore are 
chemically compatible with another ingredients, these agents exhibit 
pseudo plastic flow and have no yield value. 
Clays:- 
 There are hydrated aluminium or magnesium silicate which is 
water hydrate further to form viscous colloidal dispersions, they 
exhibit thixotropy they are more stable between pH 9 to 11. 
Magnesium Aluminum silicate is extensively used in its innocuous 
taste often produces a more acceptable suspension. Bentonite, 
hectolite and attapulgite are the other examples. Silicon dioxide and its 
hydrates are considered because their colloidal nature is similar to that 
of clays. 
 
Natural gums:- 
 Gums are water soluble and produce solution of high viscosity. 
There may be either non-ionic or anionic. Tragacanth solutions are 
very viscous and are stable over a wide range it exhibit pseudo plastic 
flow. Guar gum and locust bean gum are non-ionic. 
 Alginates exhibit Newtonian flow at low concentration it is highly 
viscous. Propylene glycol alginate is a non gelling form and exhibit 
pseudo plastic flow. Gum Arabic is water soluble with no solubility in 
organic solvents. Addition of ethanol to aqueous solution of gum 
Arabic rapidly decrease viscosity. 
 Xanthum gum is used as suspending agent because of its shear 
thining or pseudo plastic flow. Xanthum gum solving viscosity is 
almost independent of temperature and pH, this polymer is resistant to 
shear depolymerization. 
Synthetic gums:- 
 These agents have the advantage of good batch to batch uniformity 
and no microbial contamination. Carbomer is widely used because its 
solution have high viscosity and a yield value. Povidone act as 
protective colloid. Complex formations with pvp has been used to 
modify the toxicity of certain drugs. Polyvinyl allow, the viscosity in 
low and are little affected by temperature. 
Miscellaneous:- 
 Glycyrrhizin is reported to have good suspending characteristics its 
solution is pseudo plastic and exhibit thixotropy. 
Flocculating Agents:- 
 These agents enable particles to link together in loose aggregates or 
flocs. These flocs settle rapidly but are early redispersed. These agents 
are subdivided into – (a) surfaces (b) hydrophilic polymers (c) clays 
(d) electrolytes. 
Surfactants:- 
 Both ionic and non-ionic surfactants are used as flocculating agents 
and the concentration employed  range from 0.01 to 1.0% w/v non-
ionic surfactants are preferred because they are chemically compatible 
with more ingredients 
 
Hydro polymer:- 
 These have high molecular wt. with long carbon chains and include 
many material which at higher concentration are employed as suspend 
protective colloid to prevent caking and as a flocculating agent to form 
loose flocs. 
Electrolyte:- 
 They can enhance flocculation and lower the necessary surfactants 
concentration. 
Clays:- 
 Clays at concentration equal to or above 0.1% gives successful 
flocculation of most drugs suspended in a sorbitol or syrup base. 
Wetting agents:- 
 The U.S.P. 25 includes 21 surfactant as official wetting agents or 
solubilizing agents surfactants may be described as material which 
have a tendency to preferentially get located at the interfaces between 
two phase many lipophilic drugs are solubilized using surfactants for 
better bioavaibility surfactants having  HLB values between 15 to 
18 are considered to be good solubilizing agents increased distribution 
of many drugs due to miceller solubilization intestinal absorption of 
lipophilic drugs increase with non-ionic surfactants. Intestinal 
absorption of lipophilic drugs increases when tween – 80 is used as 
below concentration cmc and decreases when concentration above 
cmc. 
 Sodium carboxy methyl cellulose, bentonite, aluminium 
magnesium silicate and colloidal sillicon dioxide also aid the 
dispersion of hydrophobic drugs. 
 Glycerin, Propylene glycol are also used as wetting agents. 
 
Sweetnerss:- 
 Sweeteners are added to produce a more palatable medications. 
Drugs have a bitter taste and the suspending agents particularly clay 
may have bland taste. A viscous sweetener sorbitol solution or syrup, 
can be used to impart viscosity to retained sedimentation. 
 The common sweetening agents include mannitol, aspartame and 
sodium saccharin, due to carcinogenic potential, saccharin in the 
united states remains on a year to year basis. 
 
Additional Ingredients:- 
 Buffers:- 
 Buffers are used to control the pH of the formulation. The pH may 
be selected on the basis of solubility or stability of the drug, thebuffers 
used commonly are citric acid, sodium citrate and fumaric acid. 
Flavours:- 
 It enhance the patient acceptance of the product. Some newer 
flavours used  for children include. Raspberry, pineapple of bubble 
gum these agents are usually oils of require solvents. 
Coloring agents:- 
 Colourants are intended to provide a more aesthetic appearance of 
the final suspension. 
Preservative:- 
 Preservative are required in most suspensions because some natural 
gums are source of contamination and also the suspending agents and 
sweeteners are often good growth media for micro organisms. In some 
suspension drugs impart all is which no preservative is stable. 
Commonly used are butyl paraben, methyl paraben, propyl paraben 
and sodium benzoate. 
 
1.8 EVALUATION OF SUSPENSION8:- 
 The method used for evaluating the physical stability of suspension 
may be categorized as sedimentation method, rheological methods, 
electro kinetic methods, micro meritic methods. 
 
 
Sedimentation methods:- 
 The formation of the sediment and its resdispersibility are the two 
features related to the over all acceptability of suspension.  
 The simplest procedure for evaluation is to keep a measured 
volume of suspension in a graduated cylinder in an undisturbed state 
for certain period of time and volume of sediment is noted, which is 
expressed as ultimate height (HU). This is relation to the initial 
volume of the suspension (H0) is expressed as sedimentation ratio. 
 F = Hu/Ho 
Where,  
Hu = ultimate settled height of sediment 
Ho = original height of sediment 
F = sedimentation volume 
Redispersibility can be estimated by shaking the suspension with 
the help of a mechanical device which stimulates motion of human are 
during shaking process and can give reproducible results when used 
under controlled condition. 
Rheological Method:- 
 Evaluation of rheological behaviour of suspensions can help in 
predicting the settling pattern and can also provides due to vehicle 
particle structures. Generally lower shear rates are employed and 
samples are evaluated undisturbed. By the use of Brookfield 
viscometer with T. spindle is made to descend slowly in to suspension 
and the dial reading on the viscometer is then measure of the 
resistance the spindle meets at various level in a sediment. In this 
technique, the T-bar is continually changing position and measure 
undisturbed samples as it advances down into the suspension. 
 This technique also indicates in which level of the suspension the 
structure is greater, owing to particle agglomerating, because the T-bar 
descends as it rotates, and the bar is continually entering obtained on 
samples variously aged and stored place. Thus, using the T-bar spindle 
and the helipath, the dial reading can be against the number of turns of 
the spindle. This measurement is made on undisturbed samples of 
different ages. The result indicate how the particles are settling with 
time. In a screening study, the better suspensions show a lesser rate of 
increase of dial reading with spindle turns, i.e., the curve is horizontal 
for a longer period. 
Electro kinetic methods:- 
 The surface electronic charge or zeta potential is instrumental in 
deciding the stability of disperse phase system. The measurement of 
migration velocity of particles by electrophoresis method that 
employed a micro electrophoresis appratus. Zeta  potential produce 
more stable suspensions because aggregation was controlled and 
optimized. 
Micro meritic methods:- 
 The stability of the suspension is inter related to the size of 
particles constituting to its disperse phase. A growth in the particle 
size will results in the formulation of lump or cake destroying the 
physical structure of a suspensions. Changes in the particle size 
distribution, crystal habit are determined by microscope and coulter 
counter. 
1.9 Advantages9:- 
1. Suspension are an ideal dosage form for patients who cannot 
swallow tablet  or capsules. 
2. Since it contains finely divided particles the rate of absorption is 
quicker. 
Properties of a pharamaceutical suspension:- 
1. Particles in suspensions are small and relatively uniform in size, so 
that the product is free from a gritty texture. 
2. There is ready dispersion of any sediment on storage. 
3. The suspension is pour able 
4. After gentle shaking, the medicament stays in suspension long 
enough for a dose to be accurately measured. 
CHAPTER 2                                                  
LITERATURE REVIEW OF TASTE MASKED 
SUSPENSION 
Sambhaji pisal et al (2004), Formulated and evaluated the 
molecular properties of ciprofloxacin – Indion 234 complexes. The effect 
of batch and column process, complexation time, temperature, and pH on 
ciprofloxacin loading on indion 234 is reported. The drug – resin ration in 
complexes are 1:1.3and it is enhanced by pH and not affected by 
temperature. Indion 234 is inexpensive, and the simple technique is 
effective for bitterness masking of ciprofloxacin. 10 
Moshe gerold L et al (2005), formulated and evaluated taste-
masked formulations containing sertraline and sulfoalkyl ether 
cyclodextrin. The liquid formulations are pleasant tasting convenient to 
use, and chemically and physically stable. This formulation provides 
significant advantages over the masked non-aqueous formulation and 
other cyclodextrin – containing formulation of sertaline.11 
V.G.Jamakandi et al (2008), studied on usage and evaluation of 
stevioside as sweetening agent in salbutamol sulphate and bromhexin 
hydrochloride syrups as concentration of 0.5 and 1.0% w/v. The usage of 
stevioside can offer many advantages to patients suffering from diabetes, 
phenylketonurea and calorie conscious, ranging from pediatrics to 
geriatrics.12. 
CGG Rao et al (2004), studied on formulation of taste masked 
oral suspension of quinine sulphate by complexation, which is very much 
effective against resistant strains of plasmodium falciparum where other 
antimalarials like chloroquine, sulphadoxine – pysimethamine are 
ineffective. But, it is very bitter drug and taste should be masked by 
complexation technique using ion exchange resin and to formulated into a 
suspension.13 
Shah PP et al (2008), formulated and evaluated of taste masked 
oral reconstitutable suspension of primaquine sulphate by using beta – 
cyclodextrin catchets prepared using physical mixture (DS 24), showed 
complete bitter taste masking and easy redispersibility. 14 
Kiran Bhise et al (2008), reviwed on taste masked, design, 
evaluation of an oral formulation using ion exchange resin as drug carrier 
of diphenylhydramine hydrochloride and the cation exchange resin are 
used as Indion 234 and Tulsion 343 that contained cross linked 
polyacrylic backbone were used.15 
Patel A R et al (2008), prepared and evaluated of taste masked 
famotidine formulation using drug / beta cyclodextrin polymer ternary 
complexation as an approach for taste masking. Improvement in taste 
masking capability of cyclodextrin towards famotidin was evaluated by 
formulating a ternary complex including hydrophilic polymer HPMC as 
the third component result showed that the ternary complex better than 
binary complex.16 
Bhalerao S.S. et al (2003), studies on sustained release liquid oral 
formulation of diltiazem hydrochloride : Reconstitutable suspension, 
microspheres of diltiazem hydrochloride were prepared by non-aqueous 
emulsion solvent evaporation technique using ethyl cellulose as an 
encapsulating polymer drug loaded microsphere were formulated into a 
redispersible suspension having sustained release charecteristics.17 
LITERATURE REVIEW OF ROXITHROMYCIN FORMULATION 
Eberi, s et al (2007) studied on pole of p-glycoprotein inhibition 
for drug interactions, in vitro, the effect of macrolides on polarized p-
glycoprotein-mediated digoxin transport was investigated in caco-2 cells 
with concentrations producing 50% inhibition (IC 50) values of 1.8, 4.1, 
15.4, 21.8 an 22.7 mu mol/L for telithromycin, clarithromycin, 
roxithromycin, azithromycin and erythromycin.18 
Margaritis, VK et al (2007), studied the sinus fluid penetration of 
oral clarithromycin and azithromycin in patients with Acute rhino 
sinusitis, sinus fluid aspirates and serum sample collected 2, 4, 6, 8 and 
12 hours after the Administration of three doses of oral clarithromycin 
500 mg, twice daily or two doses of azithromycin 500 mg once a daily.19 
Hang, TS et al (2007) studied the simultaneous determination and 
pharmacokinetic study of roxithromycin and ambroxol hydrochloride in 
human plasma by LC-MS/MS in 12 healthy male Chinese volunteers 
after an over night fast by a single dose (150mg), 30mg respectively way 
crossover design with a period of 7 days washout. No significant 
difference were observed for the major pharmacokinetic parameters such 
as C-Max, T-Max, t(1/2) and AUC of both roxithromycin and Ambroxol 
between different treatment.20 
Yasuda Y et al (2007) studied the Roxithromycin favorably 
modifies the initial phase of resistance against infection with macrolide-
resistant streptococcus pneumonia in a murine pneumonia model, among 
the macrolides tested, only roxithromycin did not affect in vitro 
pneumococcal virulence factors at sub-MIC levels.21 
Oyama T et al (2007), studied the Roxithromycin inhibits tumor 
necrosis factor-alpha-induced matrix metalloproteinase-1 expression 
through regulating mitogen-activated protein kinase phasphorylation and 
ETS-1 expression in human periodontal ligament cell cultures, cultured 
cells were incubated with 1% fetal bovine serum for 24hr, followed by 
treatment with 10kg/ml TNF-alpha,  roxithromycin, and mitogen – 
activated protein kinase inhibitor at various concentration.22 
Woessner R et al (2006), studied the long term antibiotic 
treatment with roxithromycin in patients with multiple sclerosis. In study 
investigated a possible therapeutic option with antibiotics in 28 patients 
with confirmed diagnosis of MS.23 
Biradar SV et al (2006), studied the comparative study of 
approaches used to improve solubility of roxithromycin, study deals with 
exploring the effect of homogenization, homogenization followed by 
freez drying and spray drying in the presence of solubilizers on drug 
solubility I dissolution rate.24 
EI-Rabbat N et al (2006), studied A validated spectro                         
fluorometric assay for the determination of certain macrolide antibiotic in 
pharmaceutical formulations and spiked biological fluids. The method is 
based on the condensation of 10% (w/v) Malonic acid and acetic acid 
anhydride under the catalytic effect of tertiary amine groups of the 
studied macrolides.25 
Gao Y et al (2006) studied the preparation of roxithromycin – 
polymeric microspheres by the emulsion solvent diffusion method for 
taste masking, microspheres of roxithromycin with eudragit S 100 and 
silica were prepare, the effect of different polymers and drug polymer 
rations on taste masking and character of microsphere were 
quvestigated.26 
Sun J et al (2006) studied the impact of pharmaceutical dosage 
forms on pharmacokinetic of roxithromycin in healthy human volunteers. 
The degradation kinetic and product of roxithromycin were investigated 
in simulated gastric fluid and simulated intestinal fluid.27 
Suzuki M et al (2002) studied the inhibitory action of a 
macrolide antibiotic, roxithromycin, on co-simulator molecule expression 
in vitro and in vivo, result suggest that roxithromycin exerts its immune 
modulating effect through suppression of both cell activation and co-
stimulatory molecule expressions induced by antigenic stimulation.28 
Hopstaken RM et al (2002) studied is roxithromycin better than 
amoxicillin in the treatment of acute lower respiratory tract infections in 
primary care A double – blind randomized controlled trial. The surplus 
value of roxithromycin was riot confirmed. Amoxicillin remains a 
reliable first-choice Antibiotic in the treatment of LRTI.29 
Akamatsu H et al (2001), studied the effects of roxithromycin on 
adhesion molecules expressed on endothelial cells of the dermal 
microvasculature using flow cyclometer at a concentration of 0.5mkg/m 
which is lower than the therapeutic plasma concentration.30 
Kastner V et al (2001) reviewed that the influence of macrolide 
antibiotic on promotion of resistance in the oral flora of children. One 
week post treatment, up to 90% of children harbored macrolide – resistant 
strains in their oral flora.31 
Zhong DF et al (2000), studied the identification of the 
metabolites of roxithromycin in humans. Metabolites of RXM in the bile 
of four chole cystictomy patients with t-Tube drainage and in the urine 
and plasma of four healthy volunteers after signal oral doses of 150 mg of 
RXM were investigated.32 
Nakanura H et al (1999), reviewed that the clinical and 
immunoregulatory effects of roxithromycin therapy for chronic 
respiratory tract infection. Clinical parameters and neutrophil chemo 
tactic mediates in the epithelial living fluid of CLRTI patients were 
examined before and after 3 months oral administration of RXM.33 
Moniot –ville N et al (1998), studied the acceptability, efficacy 
and safety of a new pediatric oral suspension of roxithromycin in 
respiratory tract infections in 210 children, aged between 2 and 8 years. A 
dose of 5-8 mg/kg/day roxithromycin was given orally for 5-10 days.34 
Dietz A et al (1998), reviewed the severe adverse effect (churg-
strass syndrome) after the intake of macrolides like azithromycin and 
roxithromycin, are increasingly preferred over erythromycin at the ear, 
nose and throat due to improved oral reabsorption, better penetration into 
tissue, prolong half life, extended antibacterial activity and better 
pharmacokinetics.35 
Milne RJ et al (1997), studied the Tolerability of roxithromycin vs 
erythromycin in comparative clinical trials in patients with lower 
respiratory tract infections. Where stated 942 patients in 13 studies 
received erythromycin in various formulations and dosages. Most of the 
adverse events occur with erythromycin.36 
Alhymayyd MS et al (1997), studied the pharmacokinetic 
interaction between erythromycin clarithromycin roxithromycin and 
phenytoin in rat. Animals were injected with phenytoin (100mg/kg) daily 
for 4 days and then were given phenytoin 20mg/kg alone or together with 
erythromycin 50mg/kg clarithromycin 50mg/kg roxithromycin 50mg/kg 
result suggest that the harmfully drug-drug interaction occur if phenytoin 
is administered with macrolides.37 
Barreto DG et al (1996), studied the safety and efficacy of 
roxithromycin in patients with upper respiratory tract infection with the 
dose of 300mg once daily in 920 patients with acute pharyngo-
amygdalitis of probable bacterial etiology. At the end of the treatment 
92% of the 894 patients eligible for evaluation respond satisfactorily 
6.5% showed improvement and remaining 15% unsatisfactory response.38 
Gasser R et al (1996), studied the oral treatment of late lyne 
borreliosis with a combination of roxithromycin and co-trimoxazole in 
18patients and result suggested were this combination has been 
successfully in order to  thwart late lyme disease.39 
Akamatru H et al (1996), reviewed the effect of roxithromycin on 
the generation of reactive oxygen species using human neutrophils and a 
cell-free xanthene – xanthenes oxidase system was examined.40 
Shiral T et al (1995), studied the effect of 14 membered ring 
macrolide therapy on chromic respiratory tract infections and polymorph 
nuclear leukocyte activity oral administration of erythromycin (400 or 
400mg) roxithromycin (150 or 300mg) or clarithromycin (200 or 400mg) 
given daily for at least 2 months was evaluated.41 
Wenrmann T et al (1993), studied the Roxithromycin exert 
different effects on post prandial antroduodenal motor function and 
gastrointestinal symptoms in neatly subjects.42 
Costa P et al (1992), studied the disposition of roxithromycin in 
the epididymis after repeated oral administration.43 
Jehl F et al (1992), studied the penetration of roxithromycin into 
gingival tissue at steady state in 30 patients treated orally with 150 mg 
ever 12 hr for 5 days.44 
            Begue P et al (1995), reviewed the overall safety of 
roxithromycin in pediatric clinical-studies in a fetal of  477 children ,aged 
2 month to 15 years, suffering from RTI or skin and tissue infection were 
treated with roxithromycin. The mean daily dose 6 mg/kg/day 
administered b.i.d. the overall safety of roxithromycin was assessed.45 
 
  
 
 
 
 
 
 
 
CHAPTER 3 
AIM AND PLAN OF WORK 
3.1 Aim  
As per the literatures, a suitable  dosage form for paediatric patients 
will improve the compliance. Roxithromycin is an semi synthetic 
antibiotic  effective against a broad  spectrum of pathogens common in 
paediatric infection. The safety and pharmacokinetics  of a b.i.d dose of 
Roxithromycin were studied in paediatric patients from 2 month to 15 
years of age . the mean dose is 6 mg / kg /day administered will achieve 
therapeutic concentrations in children.45 
Based on the above literatures  the objective of the present study 
was focused to develop  a stable oral suspension of suitable dose of 
Roxithromycin by masking the bitter taste to make it palatable for infants 
and children.  
Although there are various technique to mask the  bitterness of a 
drug, literatures had proven that the ion exchange resin could mask the 
bitterness due to amines.  
 Since roxithromycin produces bitterness due to amines present, the 
ion exchange resins was chosen a tool for the present study to mask bitter 
taste.  
3.2 PLAN OF WORK  
The scheme of the proposed study is as  follows   
¾ Methods  
  Pre formulation study of roxithromycin  
 Formulation of taste masked roxithromycin oral suspension  
¾ Evaluation of formulated suspension 
 PH  
 Wt /ml 
 Viscosity  
 Sedimentation volume  
 Assay  
¾ Stability studies  
¾ Microbial limit test for the optimized formulation   
 
 
 
  
 
 
 
CHAPTER 4  
(Materials and Method) 
4.1.Materials                                                           
4.1.1 Ingredient used 
Materials Supplier 
Roxithromycin Shasun chemicals and 
drugs,Ltd,Pondicherry. 
Indion 204 Ion Exchange India ltd 
Sugar M.B. Sugar Mills,Maharastra 
Methyl paraben Salicylates ch. Pvt. Ltd,Hyderabad
Propyl paraben Salicylates of chemicals pvt 
ltd,Hyderabad 
Sorbitol Deosen corporation Ltd – China 
Veegum Zacfa chemicals – Gujrat 
Na Cmc Hyundae fecs co. ltd.,Korea 
Glycerin Godrej industries Ltd,Mumbai 
Na citrate Sunil chemicals thane,Mumbai 
Citric acid Sunil chemical thane,Mumbai 
Peppermint flavours Lux flavour ,Chennai 
Colour Roha dyechem, maharastra 
MAG Umang p’tech Pvt.Ltd,Chennai 
Water Madras Pharmaceuticals, Chennai 
 
4.1.2 Equipments and Instruments used 
S.No Instrument/Equipment Supplier 
1 Hot plate Remi Mumbai 
2 Shimadzu Ax zoo Digital 
Balance 
Shimadzu Japan 
3 Crest sonicator Electro lab, Chennai 
4 Magnetic stirrer Electro lab, Chennai 
5 Emulsifier Electro lab, Chennai 
6 Homogenizer Bectoehem – Hyderabad 
7 Colloidal mill Bectoehem – Hyderabad 
8 pH meter ELCO –Mumbai 
9 UV spectrometer Shimadzu,Japan. 
 
 
 
 
 
  
 
4.1.3 Drug Profile 
Roxithromycin:45, 46 
 
Category :- 
 Anti Bacterial 
Mol. formula and Wt.:- 
 C41H76N2O15,  837. 
Definition:- 
(3R,4S,5S,6R,7R,9R,1) S,12R,13S,14R)-4[(2,6 Dideoxy -3 – C-Methyl-
3-O-methyl-∝ -1-ribo-hexopyranosyl)-14-ethyl-7,12,13-trihydroxy-10-
[(E)-[(2-methoxyethoxy]imino)-3,5,7,9,11,13-hexamethyl-6-[(3,4,6-
trideoxy-3-(dimethylamino)-β--d-xylo-hexobyranosyl)oxy] 
oxacyclotetradecan-2-one. 
  
Content:- 
 96.0 percent to 102.0 percent (Anhydrous substance) 
Description:- 
 Crystalline powder 
 White in colour 
Solubility:- 
 Very slightly soluble in water, freely soluble in Acetone, in alcohol 
and in methylene chloride. It is slightly soluble in dil.Hcl.it shows 
polymorphism. 
Antimicrobial Action:- 
 It is more active than erythromycin. It inhibit protein synthesis. 
Pharmacokinetics:- 
 Following oral administration roxithromycin is absorbed, with a 
bioavaibility of about 50% peak plasma concentrations of  about 6 to 8 µg 
/ ml occurred around 2 hours after a single dose of 150mg. The mean 
peak plasma concentration of steady state after a dose of 150mg twice 
daily is 9.3 µg / ml. Absorption is reduced when taken after, but not 
before, a meal. It is widely distributed in tissue and body fluids. It is 
reported to be about 96% bound to plasma protein (mainly α1 – acid 
glycoprotein) at through and only about 86% is bound at usual peak 
concentrations. Small amount of roxithromycin are metabolized in liver, 
and the majority of the dose is excreted in the faeces as unchanged drug 
and metabolites; about 7 to 12% is excreted in urine, and up to 15% via 
lungs. 
Adverse effects and precaution:- 
 Gastrointetestinal disturbances are the most frequent adverse effect, 
but are less frequent than with erythromycin. Increases in liver enzyme 
values and hepatitis have been reported. Rashes and other 
hypersensitivity reaction, headache, dizziness, weakness and changes in 
blood cell counts have also occurred. 
Effect on pancreas:- 
 Acute pancreatitis, with duodenal inflammation, pain pancreatic 
enlargement and raised serum – amylase developed within 24hr. of 
substitution of roxithromycin for erythromycin ethyl succinate in a 
patient being treated for respiratory tract infection. 
Uses and Administration:- 
 Roxithromycin is a macrolide antibiotic with actions and uses 
similar to those of erythromycin like as urinary tract infection, respiratory 
tract infection, asthma. It is given by mouth in a doses of 150 mg twice 
daily or sometimes 300mg once daily, before meals, in the treatment of 
susceptible infections. 
 
4.1.4 Excipients Profile 
(A) Sorbitol 47 
Non Proprietory Names:- 
USPNF – Sorbitol 
IP – D-Sorbitol 
BP – Sorbitol 
Synonyms:- 
C*Pharamasorbidex: E420; 1,2,3,4,5, 
6 – Hexane Hexol; liponic 76 NC; Meritol;                                      
Neosorb ; Sorbite; D- Sorbitol 
Chemical Name and CAS Registry No:- 
 D-Glucitol [50-70-4] 
Empirical formula and mol.wt:- 
 C6H14O6, 182.17 
Structural Formula:- 
                              
H
H
H
H
OH
HO
HO
HO
HO
HO
 
 
Functional Category:- 
 Humectants; Plasticizer, Sweetning Agent, Tablet and Capsule 
diluent. 
Application in Pharmaceutical formulation:- 
 It is used as diluents in tab formula. It is particularly used in 
chewable tablet owing to its pleasant, sweet taste and cooling sensation. 
In capsule – plasticizer  
(B-) Veegum “( Magnesium Aluminum Silicate)” 
Non Proprietary Name:- 
 BP – Al.Mg. Silicate  
Synonyms:-  
Aluminosilic acid, Mg. salt, Carrisorb, Gelsorb, Mg. Al. Silicate etc. 
Chemical Name of CAS Registry no:- 
 Al. Mg. Silicate:- [ 12511-31-8] 
 Mg. Al. Silicate:- [1327-43-1] 
Empirical formula and Mol. Wt:- 
 It is a polymeric form of Magnesium., Aluminium, Silicon and 
oxygen and water. Average Chemical Analysis is expressed as oxides 
Silicon dioxide:- 61.1% 
Mg.oxide:- 13.7% 
Al.oxide: 9.3% 
Titanium oxide:- 0.1% 
Ferric oxide:- 2.9% 
Ca oxide:- 2.7% 
Structure:- 
 Composed of a three – lattice layer of octahedral alumina two 
tetrahedral silica sheets. The aluminium substituted to varying degrees by 
magnesium additional elevate include – iron, lithium, titanium, calcium 
and carbon. 
Category:-  
Adsorbent, stabilizing agent, suspending agent, viscosity increasing 
agent. 
Application in pharmaceutical formula:- 
 It is used in tablet, ointments, creams in oral suspension. It is used 
as suspending agent alone or in combination. 
Stabilizer, disintegrating Agent etc. 
Description:- 
 Off-white to creamy white, odourless, tasteless, soft, slippery small 
flakes or fine powder. 
 
 
 
Typical property:- 
 2.418 gm/ cm3 – Density  
 6 – 9.98% - Moisture Content 
Solubility – Practical insoluble in alcohol, water and organic solvents. 
Stability and storage condition:- 
 It is stable in dry condition and a wide range of pH, has base – 
exchange capacity and compatible with organic solvents. It is stored in 
well closed container and stored in cool dry place. 
Incompatibility:- 
 It is generally unstable in acidic solution below pH 3.5. it is as with 
other clays, may absorb some other drugs. this can result in low 
bioavailability. If the drug is tightly bound or slowly desorbed e.g 
amphetamine sulfate, tolbutamide ,diazepam etc. 
(C) Na-CMC 
Non-Proprietary Name:- 
IP & BP- Carmellose sodium 
USP – Carboxymethyl cellulose sodium. 
Synonym:- 
 Cellulose gum, sod cellulose glucolate. 
Chemical name and CAS Registry no:- 
 Cellulose, Carboxymethyl ether, sodium salt (9004-32-4) 
Empirical formula and Mol.wt:- 
 USP describes its sod salt of a poly carboxy methyl ether   of 
cellulose. 
Mol.wt.:- 
 9000 – 70,000 
Structure:- 
O
O O
O
OH
OHOH
CH2OCH2COONa
 
Category:- 
 Coating Agent, Stabilizing Agent, Suspending Agent, Tablet and 
Capsule disintegrator, tablet binder, viscosity increasing Agent, Water 
Absorbing Agent. 
Application:- 
  It is used as a suspending agent, binding agent and as a base for 
gels and pastes. 
Description:- 
 White to almost white, odourless, granular powder. 
 
 
Typical Property:- 
 Density (Bulk) – 0.52g/cm3 
    (Tapped) – 0.78g/cm3  
     pKa – 4.30 
 M.P –becomes  Browns at approximately 2270c and chars at 
2520’c. 
Moisture content:- 
 Typically contain less than 10%water however it is hygroscopic 
and absorb significant amount of water at a temperature up370c to at 
relative humidity of about 80%. 
Solubility:- 
 Practically insoluble in acetone, ether, toluene, and ethanol (95%) 
easily dispersed in water.    
Viscosity:- 
 Viscosity    Grade 
10-15  –  Akucell Af0305 – Low viscosity 
1500 – 2500 –  Akucell Af 2785 – high viscosity 
8000 – 12,000 –  Akucell Af 3085 – Medium viscosity  
Stability and storage:- 
 It is stable though hygroscopic material. Under high humidity 
condition. Its absorption high amount of water (>50%). Aqueous solution 
stable at pH 2-10 below pH 2 solution precipitate and put 10-viscosity 
decreased. It is sterilized at dry state at 1600c for 1hr. Sterilization by 
gamaradiation also reduce its viscosity.   
 Antimicrobial preservatives added for prolong stores it is stored in 
well closed container in cool, dry place. 
Incompatibility:- 
 Incompatible with strong acidic solution and with the soluble salts 
of iron and some other metals eg-Aluminium, Mercury, iron and zinc. 
Precipitate occur with ethanol (95%) and precipitation occurs at ph<2. It  
form’s complex coacervates with pectin and gelatin. 
Safety:- 
 It is non toxic and non irritant material oral consumption of large 
amount of carboxy methyl cellulose sodium have a laxative effect. The 
WHO has not specified an acceptable daily intake for sod cmc as a food 
additives. 
LD(50) (Guinea pig, oral) – 16g/kg 
LD 50 (rat, oral) – 27g/kg   
 
 
 
(d) Glycerin 
Non proprietary name :- BP – Glycerol 
      IP – Concentrate Glycerin 
      USP – Glycerin 
Synonyms:- 
 Glycon G – 100; 1,2,3 – Propentriol; trihydrooxy propane glycerol. 
Chemical name and CAS Registory No:- 
 Propane – 1,2,3 – triol (56 – 81 – 5) 
Empirical formula and Mol.Wt. – c311803   92.09     
Structure:- 
OH
OH
OH
 
Category: 
 Antimicrobial preservative, emollient, humectants, Plasticizer, 
Solvents, Sweetening Agent, tonicity agent. 
Application: 
 It is used in Pharmaceutical formulation. It is used as a 
antimicrobial preservative for the protection to microbial growth and it is 
used as emollient, humectants. It is used as a plasticizer in formulation 
and act as a solvent and sometimes it is used as a sweetning agent also. 
Description: 
 Clear, colourless, viscous, hygroscopic liquid, sweet taste. 
Typical property: 
       Boiling point – 290oc  
Density  –       1.2656g/cm3 at 15oc 
             1.2638g/cm3 at 20oc 
      1.2620g/cm3 at 25oc 
Freezing point – 10% solution (-1.60c) 
Melting point  – 17.8oc 
Osmolarity    –   a 2.6% r/v aq/solution is osmotic with serum. 
Solubility: 
 Acetone – slightly soluble 
 Benzene – practically insoluble 
 Chloroform – practically insoluble 
 Ethanol (95%) – soluble 
 Ether – 1 in 500 
Water – soluble 
 Surface tension – 63.4 (dynes/cm) at 20oc 
 
 
 
Viscosity: 
Concentration of.Aqueous solution of glycerin – Viscosity at 20oc 
   5 –          1.143 
10 –      1.311 
25 –      2.095 
                                              50 –      6.05 
60 –      10.96 
Stability and storage condition: 
 It is decomposes on heating with the evolution of toxin acrolein. 
Mixture of glycerin with water, ethanol, propylene glycol is stable. When 
stored at low temperature it crystalline and not melt until warmed upto 
20oc. it is stored in airtight container in a cool, dry place. 
Incompatibility: 
 It may explode when mixed with strong oxidizing agent such as 
chromium trioxide, potassium chlorate. Black discolouration occur in the 
presence of light or an contact with zinc oxide or basic bismuth. 
Safety: 
 Large dose may produce headache, thirst, nausea and 
hyperglycemia. 
 The therapeutic paranteral Administration of very large dose of 
glycerin may induce renal failure, hemolytic, hemoglobinuria. 
(E) Na – Citrate 
Non Proprietary Name: 
 BP – Sod citrate 
Ph EV – Natril citras 
Synonyms:  
 Citric acid trisodium salt; E 331; sodium citrate tertiary; trisodium 
citrate. 
Empirical formula and Mol.Wt: 
 C6H5Na3O72H20    294.10 
Structure: 
O O
O
OHNaO ONa
NaO
.2H2O
 
 
Category: 
 Alkalizing Agent, Buffering Agent, emulsifier, sequestering Agent. 
 
Application: 
 It is used in pharmaceutical formulation as a Alkalizing Agent and 
maintain the pH as a buffering Agent. It is used as a emulsifier and 
sequestering agent also. 
Description: 
 It consist of odourless, colourless, monoclinic crystals or white 
crystalline powder with a cooling saline taste. It is slightly deliquescent in 
moist air and in warm dry air it is efflorescent. 
Typical property: 
 Acidity / Alkalinity: pH – 7-9 (5% w/v aq.solution) 
Density (bulk) 1.12g/cm3 
Density (Tapped) 0.99 g/cm3 
Density (True) – 1.19g/cm3.       
Melting point:  
 Converts to the anhydrous forms at 150oc 
Osmolarity: 
 3.02% w/v aq.soln in iso-osmotic with serum 
Particle size distribution: 
 Various size are available. 
Solubility: 
 Soluble 1 in 1.5 of water, 1 in 0.6 of boiling water, practically 
insoluble in ethanol (95%). 
Stability and storage condition: 
 It is stable material Aqueous solution may be sterilized by 
Autoclaving on storage aq.soln may cause the separation of small, solid 
particles from glass container. 
 Bulk material should be stored in airtight container in cool dry 
place. 
Incompatibility: 
 It is slightly Alkaline and its salts may be precipitated from their 
Aqueous or hydro alcohol solution. 
 Calcium and strontium salts will cause precipitation of the 
corresponding citrates. Other incompatibility includes bases, reducing 
agent, oxidizing agents. 
Safety: 
 After ingestion, sodium citrate is Absorbed and metabolized to 
bicarbonate. It is nontoxic and non-irritant excipients, excessive 
consumption may cause gastro intestinal discomfort or diarrohea. 
 
 
 
 
 
(F) Citric Acid 
Non proprietary name:  
BP – Citric acid monohydrate 
 IP – Citric acid 
Synonym: 
 2 – hydroxy – 1,2,3 – Propantricarboxylic acid monohydrate. 
Ch.name and CAS Registry No: 
 2 – hydroxy – 1,2,3 – Propantricarboxylic acid monohydrate (5943 
– 29 -1) 
Empirical formula and mol.wt: 
C6H807H20   (210.14) 
Structure:  
O O
O
OHHO OH
HO
.H2O
 
Category: 
 Acidifying agent, antioxidant, buffering Agent, Chelating Agent, 
Flavour enhancer. 
 
Application: 
 It is used as Acidifying Agent and it is also used as Antioxidant to 
prevent product from oxidation. It is used as buffering agent and 
complexing Agent also. 
Description: 
 Colorless or translucent crystals, or as a white crystalline, 
efflorescent powder. Odourless and strong Acidic taste. Crystal structure 
is orthorhombic. 
Typical Property: 
 Acidity / Alkalinity : PH – 2.2 (1%w/v aqueous solution) 
pka1 – 3.128 at 250c   
pka2 – 4.761 at 250c 
pka3 – 6.396 at 250c 
Density – 1.542g/cm3 
Hygroscopicity: 
 At pH less than about 65%. At pH below 65-75% citric acid 
monohydrate absorb insignificant amount of moisture but under more 
humid condition substantial amount of water are absorbed. 
Melting point: 
 1000c (soften at 750c) 
 
Solubility: 
 Soluble 1 in 1.5 parts of ethanol and 1 in less than 1 part of water. 
Sparingly soluble in ether. 
Stability and storage condition: 
 It loses water of crystallization in dry air or when heated to about 
400c. it is slightly deliquescent in moist air. Dilute aqueous solution may 
ferment on standing. 
 Bulk citric acid stored in airtight container in cool, dry place. 
(G) Methyl Paraben 
Synonyms:  
 E 218; 4-hydroxybenzoic acid methyl ester; methyl ester; methyl 
P-hydroxy benzoate. 
Chemical Name and CAS No: 
 Methyl 4-hydroxybenzoate  
(99-76-3) 
Empirical formula: 
 C8H803 
Molecular wt.: 
152.15 
 
 
Category: 
Antimicrobial preservative. 
Description: 
 Methyl paraben crystalline powder. It is odourless or almost 
colourless and has slight burning taste. 
Typical properties: 
 Antimicrobial Activity: Exhibit Antimicrobial activity between PH 
4-8. 
Density (True) : 1.352g/cm3 
Solubility : 
 Soluble in various solvents like ethanol, ethanol 95%, ethanol 50%, 
ether, glycerin, mineral oil, peanut oil, propylene glycol and water in 
different proportionate. 
Incompatibility: 
 The Antimicrobial activity of methyl paraben and other paraben is 
considerably reduced in the presence of non ionic surfactants, such as 
polysorbate 80, as a result of miscellization. Incompatibilities with other 
substances such as betonite, magnesium trisilicate, talc, tragacanth, 
sodium alginate, essential oils, sorbitol and atropine have been reported. 
 
 
Safety: 
 Parabens are non mutagenic, non teratogenic and non carcinogenic.     
Stability and storage: 
 Aqueous solution at pH 3-6 are stable for upto 4 years at room 
temperature. While at pH 8 it undergoes rapid hydrolysis methylparaben 
should be stored in well-closed container in a cool dry, place. 
(H) Propyl Paraben 
Synonym: 
 H-Hydroxybenzoic acid propylester; p – hydroxybenzoate. 
Chemical name and CAS no: 
 Propyl 4-hydroxybenzoate (94-13-3) 
Empirical formula: 
 C10H1203 
Molecular wt.: 
 180.20 
Category: 
 Antimicrobial preservative. 
 
Description: 
 It occurs as white, crystalline, colorless and tasteless powder. 
 
Incompability: 
 The Antimicrobial activity of methyl paraben and other parabens is 
considerably reduced in the presence of nonionic surfactants, as a result 
of micellization. 
Safety: 
 Propyl paraben and other parabens are widely used as antimicrobial 
preservatives in cosmetics, food products and oral formulations.  Due to 
the irritant potential of the parabens now they are regarded as being 
unsuitable for injections and ophthalmic preparations. 
Stability and storage: 
 Aqueous solutions at pH 3-6 are stable for up to 4 years at room 
temperature while at pH 8 it undergoes rapidly hydrolysis. Methyl 
paraben should be stored in well closed container in a cool dry place. 
(I) Sugar (Sucrose) 
Synonyms: 
 Best sugar, Cane sugar, Refined sugar, Saccharose, Sugar etc. 
Chemical name and CAS No: 
 β-D-Fructofuranosyl - ∝ -D-glucopyranoside. (57-50-1)   
Empirical formula: 
 C12H22011 
 
Molecular wt.: 
 342.30 
 
Structure: 
OH
OH
OH
OH
OH
OH
OH
OH
O
O
O
 
 
 
Category: 
 Coating Agent, Granulating Agent, Sugar coating Adjunct, 
Suspending Agent, Sweetning Agent, Tablet binder, Tablet filler, 
Viscosity increasing Agent. 
Description: 
 Colorless crystals, as crystalline masses or blocks, or as a white 
crystalline powder odorless and sweet taste. 
 
 
Typical property: 
 Density (Bulk) – 0.93g/cm3 (Crystalline sucrose) 
    - 0.60g/cm3 (Powder sucrose) 
pka = 12.62 
Solubility: 
 Crystalline free flowing where as powder sucrose is a cohesive 
solid. 
Melting point – 160-1260c 
Moisture content – Finally divided sucrose is hygroscopic and absorb 
upto 1% water. 
Osmolarity: 
 A 3.25% w/v aqueous solution is iso osmotic with serum. 
Solubility: 
 Chloroform – Practically insoluble 
 Ethanol – 1 in 400 
 Water – 1 in 0.2 at 1000c 
Propane 2 – 1 in 400 
Specific gravity: 
 At 2% sucrose solution – 1.0060 
 At 6% sucrose solution – 1.0219 
10% sucrose solution – 1.0381 
20% sucrose solution – 1.0810 
50% sucrose solution – 1.2296 
Stability: 
 It has good stability at room and at moderate pH it Absorb 1% 
moisture which is realized at temperature increasing 900c at 1600c it  
caramelizes at dilute solution liable to fermentation by microorganism but 
increases concentration resist decomposition aqueous solution sterilized 
by Autoclaving or filtration. Bulk material stored in well closed container 
in cool and dry place. 
Incompability: 
 It is powder form contaminated lead to incompatibility with active 
ingredient. Example – Ascorbic acid is also contaminated by sulfite from 
refining process.  
 Sucrose may attack aluminum closure. 
Safety: 
 Sucrose is hydrolyzed in small intestine by sucrose enzyme in to 
fructose and dextrose and then Absorbed. 
 It is widely considered to be more carcinogenic than other 
carbohydrate. Since it is more easily connected to dental plaque. For this 
reason, its use in oral formulation is declining. 
 It is also associated with obesity, renal damage, and a no.of other 
disease. 
L D (50) (mouse) IP – 14g/kg 
L D (50) ,rat (oral) – 29.7g/kg   
(J) Indion 20448 (http://www.ionindia.com) 
 Indion 204 is based on a cross linked polyacrylic matrix. It is a 
high purity grade weak acid cation exchange resin. 
 
Description: 
 White to pale cream colored powder, free from foreign matter. 
Typical property: 
 Particle size distribution 
Retain on 100# : 1% 
      200#: 45% 
Solubility: 
 Insoluble in water and in common solvents. 
Functional group: 
 Carboxylic acid 
Moisture content: 5% 
Ion Exchange capacity : 10millieq/g 
 
Toxicity :   
Indion 204 is a high molecular weight cross – linked polymer and 
hence not absorbed by body tissue. 
 
Stability and storage: 
 It is hygroscopic in nature and hence should be stored in an airtight 
container. 
 The theoretical quality of drug, which can be complexed with 
resins, depends upon two factors, viz. 
1. The exchange capacity of resin 
2. The equivalent weight of the drug 
Generally for the drugs having a molecular weight between 300 and 
500, the required drug resin is 1:2.25, while for the drug have high 
molecular weight less than 600, the required drug resin ratio is 1:4. 
Application: 
 Taste making 
 Sustained release 
 Vit. B12 stabilizing 
 Tablet disintegrate     
 
 Chapter 5 
5.1 Method  
5.1.1 Preformulation49 
 Preformulation is the first step in the rational development of 
dosage form of a drug substance and it is defined as investigation of 
physical chemical properties of a drug substance alone and when 
combined with excipients. 
5.1.2 Compatibility study50 
 Compatibility studies are done to find our whether there is any 
interaction between drug and excipients. The drug is mixed with the 
excipients in the ratio 1:1 and 1:5 and observations were noted. 
Inference: 
 Observations were concluded that, the excipients selected for 
formulation of Roxithromycin suspensions. 
Accelerated conditions: 
 This study is done by inducing a stress at different temperature. 
The rate of the reaction increases of the temperature. 
I - 400c; pH – 75% 
II - 250c; pH – 60% 
III - Room temperature 
 The drug is mixed with the excipients in the ratio 1:1 and are 
subjected to different temperature. The study was done for one week and 
the observations are given in the table. 
5.1.3 Preformulation study of Roxithromycin49 
Table No 3 
1 Appearance white or crystalline powder 
2 Solubility Very slightly soluble in water, freely 
soluble in acetone, in alcohol and in 
methylene chloride. It is slightly 
soluble in dilute Hcl acid. 
3 Identification  
 A) Sp.optical Rotation -93 to -96 
 B) By IR Sample Peak size and retention time 
same as reference solution. 
4 pH Its pH was tested by 10% w/v solution 
of Roxithromycin and the value is 4.5. 
5 Content 96 to 102 percent (Anhydrous sub) 
6 Heavy metals Maximum 10PPM 
7 Related substance (By 
liquid chromatography) 
0.05 
8 Water Maximum 3%, on 0.200g 
9 Sulphated Ash Maximum 0.1%, determined on 1.0g 
10 Assay P – cymene : 0.8% to 2.5% 
Camphor : 5% to 15% 
Borneol : 1.5% to 5% 
∝ -terpeneol : 1% to 2.6% 
5.1.4. INFRARED SPECTROSCOPY 
  By using FTIR technique Roxithromycin and polymers like, 
sodium carboxy methyl cellulose and Roxithromycin optimum formulation 
were identified. 
  The interpretation are shown in following tables  
TABLE NO.4 
IR SPECTRA DATA [POTASSIUM BROMIDE PELLETS] 
FOR PURE ROXITHROMYCIN 
Frequency cm-1 Groups Assigned 
3464 O – H stretching 
2980 C – H stretching 
1728 C = O stretching 
1172 C – O stretching 
1077 C – O stretching 
1012 C – O stretching 
 
 
 
TABLE NO.5 
IR SPECTRA DATA [POTASSIUM BROMIDE PELLETS] 
FOR PURE SODIUM CARBOXY METHYL CELLULOSE 
 
 
 
Frequency cm-1 Groups Assigned 
3448 O – H stretching 
2925 C – H stretching 
1618 C = O stretching 
1422 C – H stretching 
1059 C – O stretching 
 
 
 
 
 
 
 
 
TABLE NO.6 
IR SPECTRA DATA [POTASSIUM BROMIDE PELLETS] 
FOR OPTIMUM ROXITHROMYCIN 
 FORMULATION(RXS06) 
 
 
Frequency cm-1 Groups Assigned 
3464 O – H stretching 
2979 C – H stretching 
1730 C = O stretching 
1171 C – O stretching 
1077 C – O stretching 
1012 C – O stretching 
 
 
 
 
 
 
 
REPORT 
The spectrum was interpreted and identified as , Roxithromycin , and 
sodium carboxy methyl cellulose. The presence of excipients such as sodium 
carboxymethyl cellulose along with the drug does not cause any interaction.
                                              5.2 Compatibility study of Roxithromycin with Excipients    
Table no.7  
Physical Observation Ratio First day Fourth day After one weak Drug Excipients  RT 25OC 40OC RT 25OC 40OC RT 25OC 40OC 
R Indion 204 1:1 ND ND ND ND ND ND ND ND ND 
R Methyl Paraben 1:1 ND ND ND ND ND ND ND ND ND 
R Propyl paraben 1:1 ND ND ND ND ND ND ND ND ND 
R Sorbitol 1:1 ND ND ND ND ND ND ND ND ND 
R Veegum 1:1 ND ND ND ND ND ND ND ND ND 
R Na CMC 1:1 ND ND ND ND ND ND ND ND ND 
R Na Citrate 1:1 ND ND ND ND ND ND ND ND ND 
R Citric acid 1:1 ND ND ND ND ND ND ND ND ND 
R – Roxithromycin    ND – Non detectable     RT-Room temperature 
5.3 Formulation trials for Roxithromycin suspension 
Batch Size : 1000ml 
Table No:-8 
S.No Ingredients UOM  Rxso1 Rxso2  Rxso3 Rxso4  Rxso5 Rxso6 
 Roxithromycin  g 11  11 11 11 11 11 
 Indian 204 g  - 40 35 35 35 35 
 Sugar  g - 500 500 500 500 500 
 Methyl paraben  g 1.8 1.8 1.8 1.8 1.8 1.8 
 Propyl paraben  g  0.2 0.2 0.2 0.2 0.2 0.2 
 Sorbitol g 60  - - - 60 60 
 Veegum g 3 3 3 3 - - 
 Na cmc g - - 2 2 2 2 
 Glycerin g 30 30 - - - 30 
 Na Citrate g 3 3 3 6 6 6 
 Citric acid g 0.5 0.5 0.5 1 1 1 
 Aspartame g 1 1 - - - - 
 Pipermint flavor g 5 5 5 5 5 5 
 Colour (senset yellow) g 0.044 0.044 0.044 0.044 0.044 0.044 
 Mono Ammonium glycyrizinate   g 5 5 5 - - - 
 Water L 9.5 9.5 9.5 9.5 9.5 9.5 
5.4 Manufacturing Process 
PREPARATION OF SUSPENSION 
STEP 1 
 Transferred 120ml deionized water in to a cleaned stainless steel vessels 
disperse slowly under stirring 35gm of resin stir for 15min. Add slowly under 
stirring 11gm of Roxithromycin into the tank continue stirring for further ½ 
hour. During the stirring process close the tank with S.S. lid. 
STEP 2 
 Transfer 300 ml of deionised water in a suitable jacketed S.S.Vessels. 
Boil the water and add methyl and propyl paraben in to it also add sugar into it 
under stirring continue heating the solution till the temperature of the syrup 
attains 120oc ensure the complete  dissolution of the sugar. Continue stirring 
during this process. Discontinue heating add sorbitol in to sugar syrup continue 
stirring for sometime, till the temperature comes down to approximately 800c 
filter the hot sugar syrup through muslin cloth and transfer the same into the 
tank from step 1. Continue stirring after addition of sugar syrup. 
 
 
STEP 3 
 Transfer 15gm of glycerin into a cleaned S.S. vessel and under stirring 
sodium CMC uniform suspension achieved. Transfer this to the manufacturing 
tank in step 1 continue stirring after addition. 
STEP 4 
 Transfer 15gm glycerin in to cleaned S.S tank and add 5gm (MAG) mono 
ammonium glycerrhzinate under stirring and dissolve completely in glycerin 
transfer this in to step 1. 
STEP 5 
 Transfer 10ml deionised water in to S.S. vessel and add sodium citrate 
6gm stir till it dissolve. Add citric acid and stirr till it dissolves. Transfer it in to 
step 1. Transfer 2ml water in vessels add sunset yellow supra colour and stir till 
it dissolve. Transfer same into the ufg tank and the transfer the pippermint 
flavor in to a S.S vessel and then it transfer in to step 1. 
STEP 6 
 Check pH adjust to 4.5 with either dilute with NaoH or Hcl. Stir continue 
make the volume upto 1 liter and stir for 15 minute. Stop stirring close the tank 
with suitable lid. 
 
 
5.5 PARAMETER EVALUATED FOR ORAL SUSPENSION51 
 The parameters evaluated for oral suspension are as follows weight per 
ml, pH Viscosity ,percentage sedimentation volume, Assay, Antimicrobial 
studies. 
5.5.1 Appearance: 
 The appearance in a graduated glass cylinder or transparent glass 
container is noted. 
5.5.2 Color, odor, and Taste:- 
 These characteristic are specially important in orally administered 
suspensions. Variation in colour often indicates poor distribution and 
differences in particle size. Change in colour, odour and taste can also indicate 
chemical instability 
5.5.3 Weight per ml:- 
 A Pre weighed 25 ml volumetric flask was taken and the oral suspension 
was added up to the mark. The net volume is noted. Then weighed the above 
volumetric flask to evaluate weight per ml. 
 
5.5.4: pH:- 
 It is an Important parameter, which reflects the stability of suspension. 
Any change in pH indicates the degradation of drug or other ingredients. For 
stabilizing the suspension the pH has to be maintained by the addition of buffer. 
The pH was checked initially and the after 15 days. This was measured by pH 
meter 
5.5.5 Viscosity:- 
It is the measure of the internal friction of a fluid. It is a rheological 
consideration, which indicates the setting of dispersed particles and change in. 
flow property of the suspension, when container is shaked and when the product 
is dispensed from the bottle Brookfield viscometer in a std. condition was used 
to measure it. here viscosity was measured for all formulations in standard 
condition. 
5.5.6 Particle size measurement:- 
Particle size measurement permits evaluation of aggregation of crystal growth 
any change in particle size affects the sedimentation rate, care of 
redispersebility, making and efficacy properties of a disperse system. 
The  various methods used for the determination of average particle size, they 
are, 
• Microscopic Technique. 
• Sieving Technique. 
•  Sedimentation technique 
• Coulter counter method. 
5.5.7 Percentage sedimentation volume: 
Sedimentation volume is important to measure since it affects the stability of 
suspension. Here  the sedimentation volume was measured in percentage for 
determining sedimentation volume, the suspension was poured in to 100 ml 
uniform. Graduated stopped cylinder and stored at room temp. [RT] without any 
external disturbances. The percentage volume of sediment formed was 
measured initially and after four weeks. 
F = HU/HO x 100 
Where 
HU = Ultimate settled height of sediment 
HO = Original height of sediment and 
F = The percentage sediment volume. 
5.5.8 Assay of Roxithromycin suspension:- 
Solvent preparation:- 
 Take 125 ml of absolute ethane in 250 ml volumetric flask add 10 ml of 
conc. Hydrochloric acid and make up to mark with distilled water. 
Reagent preparation:- 
Weight 200 mg of 4 – diethyl amino benzaldehyde in 10 ml volumetric flask, 
dissolve in absolute ethanol. Add 0.1 ml of conc. Hydrochloric acid and make 
up to the mark with absolute ethanol.   
Standard preparation:- 
Weigh accurately 50 mg of Roxithromycin working standard in 25 ml 
volumetric flask dissolve in glacial acetic acid and make up to the mark with 
glacial acetic acid. Pipette 5 ml of the standard preparation in to 25 ml 
volumetric flask, add 1 ml of reagent, shake well and keep in boiling water bath 
for 30 min. among with sample preparation. 
  
Sample preparation:- 
Weight accurately suspension equivalent to 100 mg of Roxithromycin from a 
well – shaken bottle, in a 100 ml volumetric flask. Add 10 ml of solvent shake 
the flask. Add the solvent up to the mark and keep in sonicator bath for 1 hr. 
filter through whatman no. 41. Pipette 25 ml of the filtrate and transfer it to 100 
ml separating funnel. Add 2 ml of strong ammonia solution and extract with 20 
+ 10 + 10 ml of chloroform. Collect 50 ml of the chloroform layer in 50 ml 
volumetric flask and make up to the mark with chloroform if necessary.  Add 
0.5 gm of sodium chloride to it and shake for a while. Evaporate 20 ml of 
chloroform layer in 25 ml volumetric flask on water bath taking care to avoid 
expulsion of chloroform from the volumetric flask during evaporation. Add 5 
ml of glacial acetic acid shake well add 1 ml of reagent shake well and keep on 
boiling water for 30 min to develop a colour. After 30minute make up to mark 
with glacial acetic acid. Read the colour at 690nm against absolute ethanol as a 
blank preparation simultaneously using 5.0ml of glacial acetic acid, instead of 
sample and treating in a similar manner as done for standard and sample 
preparation from the Absorbance of standard and sample preparation calculate 
the content of Roxithromycin in each 5 ml of suspension. 
Calculation:- 
mlXwtXpuritystdXXX
wtspl
XXwtStdX
AbsStd
Abssample /5
10025
25
25
50
.
100
25
5
25
..
..
.  
5.5.9 Stability studies:-  
The most common form of physical instability occurring in suspensions is 
the setting out of the solid phase with the formation of sediment which is 
difficult to re-disperse on shaking  
 Crystal growth is also a cause of physical deterioration in some 
suspensions. Acceleration of crystal growth may be achieved by simulating the 
temperature fluctuations occurring under normal stage conditions, but at greatly 
increased frequency. 
 An ideal form apart from other dosage requirement should provide 
consistency of drug content and release through out its shelf life. The 
formulated taste masked roxithromycin oral suspension was packed in 50 ml 
amber coloured glass bottles and stored at a temperature of 40oC± 2oC and RH 
75oC± 5% and a temperature. The product were stored for a period of 60days in 
the above mentioned conditions. The induct was analyzed at initial, 30 days and 
60 days of storage. 
 After the storage period the formulation were evaluated for the following: 
• Appearance 
• Wt/ml 
• pH 
• Viscosity 
• Particle sedimentation volume. 
• Assay 
5.5.10: Microbial limit test for the optimized formulation: 
 The product was subjected Total Bacterial count (TBC), Total fungal 
count (TFC) and for specified microorganism Escherichia coli. 
Methods:- 
TBC(Total Bacteria Count):- 
 Add 1 ml of pretreated sample to sterile Petridish and pour about 20 ml of 
sterile nutrient agar medium in to the plate and mix well by rotating in clock 
wise and anti clock wise direction.  
 2 plates are incubate at 35 oC-37 oC for 48 hrs. After incubation count the 
number of colony forming units and express the result as average for the 2 
plates in terms of the number of colonies per ml 
TFC(Total fungal count):- 
Proceed as per the procedure described in the test for bacteria but use 
potato dextrose agar medium in place of nutrient agar and incubate the plates at 
20 oC - 25 oC for 5 days. 
For specified microorganism (E. coli): 
 The test was carried out as per the official method with the limitation 
only to primary test, in which 1.0 ml of sample was added to a tube containing 5 
ml of macconkey broth and was incubated at 36 oC to 38 oC for 48 hrs and the 
result were interpreted.     
 
 
 
 
 
CHAPTER – 6 
Result and Discussion 
6.1 Evaluation of Roxithromycin oral suspension 
 Based on the objective and plan of work, after preliminary studies six 
trial formulations of Roxithromycin oral suspension were formulated. The 
formulated trial batches were designed as Rxs01, Rx s02, Rxs03, Rxs04, Rxs05, 
and Rxs06. 
 All trial formulation were evaluated by selected parameter study. There 
parameter studies were (i) Evaluation of oral suspension and (ii) stability 
studies. 
6.1.1 Parameter Evaluated for oral suspension 
 The import-out parameter evaluated includes pH, weight per ml, 
viscosity, particle size determination, percentage sedimentation volume, assay, 
microbiological analysis. 
6.1.2 pH:- 
 The pH of oral suspension was checked since it indicates the stability of 
the drug. This parameter was evaluated initially and at 15 days. The observed 
mean values for all six trial batches are given table no.6. The observed data 
showed no deviation in pH for all six trial batches. The pH  value ranged from 4 
to 5.  
pH values observed initially and after 15 days. 
Table no.9 
Formulations pH values initially pH values after 15 days 
RxS01 4.91 4.87 
RxS02 4.12 5.19 
RxS03 4.92 5.02 
RxS04 5.07 5.11 
RxS05 4.81 4.93 
RxS06 4.51 4.56 
 
 
 
 
6.1.3 Weigh Per ml:- 
Weight per ml of the oral suspension was checked for all six trail batches. 
The weight per ml of the six trial between 1.21 to 1.24. The details data given in  
Table no. 10 
S.No. Formulations Weight Per ml 
(initially) 
Weight per ml 
(After 15 days) 
1 RxS01 1.24 1.24 
2 RxS02 1.23 1.22 
3 RxS03 1.23 1.24 
4 RxS04 1.21 1.21 
5 RxS05 1.24 1.23 
6 RxS06 1.22 1.22 
 
 6.1.4 Viscosity: The viscosity of six trial batches of oral suspensions was 
checked. Non-Newtonian fluids do not show a characteristic viscosity over a 
range of test conditions. Only an apparent viscosity can be measured, and its 
values depends on the conditions must be standardized  with regard to the extent 
of premixing of the sample prior to the test, temperature, instrument speed and 
the spindle used. The observed data detailed given in table no.11 
Table no. 11 
S.No. Formulations Viscosity 
(initially CPS) 
After 15 
days(CPS) 
1 RxS01 480 488 
2 RxS02 490 498 
3 RxS03 468 475 
4 RxS04 370 379 
5 RxS05 390 372 
6 RxS06 460 465 
 
6.1.5 PARTICLE SIZE ANALYSIS 
For particle size Analysis for formulation RxS01 trial 
Table no. 12 
S.No. Size range 
(micron) 
Mean size 
range (micron)
No. of 
particles 
% in each 
range 
1 0-100 50 64 32 
2 100-200 150 50 25 
3 200-300 250 45 22.5 
4 300-400 350 41 20.5 
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For particle size Analysis for formulation RxS02 trial 
Table no. 13 
S.No. Size range Mean size range No. of % in each 
(micron) (micron) particles range 
1 0-100 50 85 42.5 
2 100-200 150 64 32 
3 200-300 250 30 15 
4 300-400 350 21 10.5 
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For particle size Analysis for formulation RxS03 trial 
Table no. 14 
S.No. Size range 
(micron) 
Mean size 
range (micron)
No. of 
particles 
% in each 
range 
1 0-100 50 70 35 
2 100-200 150 55 27.5 
3 200-300 250 30 15 
4 300-400 350 45 22.5 
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For particle size Analysis for formulation RxS04 trial 
Table no. 15 
S.No. Size range 
(micron) 
Mean size 
range (micron)
No. of 
particles 
% in each 
range 
1 0-100 50 81 40.5 
2 100-200 150 70 35 
3 200-300 250 34 17 
4 300-400 350 16 8 
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Particle size Analysis for formulation RxS05 trial 
Table no. 16 
S.No. Size range 
(micron) 
Mean size 
range (micron)
No. of 
particles 
% in each 
range 
1 0-100 50 64 32 
2 100-200 150 50 25 
3 200-300 250 45 22.5 
4 300-400 350 41 20.5 
010
20
30
40
50
60
70
0-100 100-200 200-300 300-400
64
50
45
41
32
25
22.5
20.5
No. of particles
% in each range
 
Particle size Analysis for formulation RxS06 trial 
Table no. 17 
S.No. Size range 
(micron) 
Mean size 
range (micron)
No. of 
particles 
% in each 
range 
1 0-100 50 90 45 
2 100-200 150 50 25 
3 200-300 250 36 18 
4 300-400 350 24 12 
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6.1.6 Percentage sedimentation volume 
It was checked for all trial formulations after 30 days. The detailed data is given 
in Table no.8 Among the six formulation 
RxS03 and RxS06 gave significantly best percentage sedimentation volume. 
Observed percentage sedimentation volume for all trial formulation after 30 
days  
Table No: 18 
S.No. Formulations Sedimentation Volume Average 
1 RxS01 96, 99, 98, 96, 98 97.4 
2 RxS02 96,98,99,95,97.5 98 
3 RxS03 100, 100, 100, 100, 100 100 
4 RxS04 99, 99, 99, 99, 98 98.8 
5 RxS05 99, 99, 97, 99, 99 98.6 
6 RxS06 100, 100, 100, 100, 100 100 
 6.1.7 Assay:- 
 The assay of oral suspension is done by UV method. All the six batches 
observed within the standard range of 90% to 110%. The observed values are 
given in Table No.19 
Assay of Roxithromycin suspension 
Table No.19 
S.No. Formulation Assay % 
1 RxS01 92.15 
2 RxS02 92.47 
3 RxS03 94.015 
4 RxS04 93.0 
5 RxS05 93.16 
6 RxS06 94.47 
    
Calculation: For RxSo6 Trial 
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6.1.8 Stability studies conducted after one month and two month in two 
conditions of 40oC and 31 oC (Room temperature) 
6.1.8.1 Stability studies: 
Stability study tests are used to find out whether the formulations are 
maintaining their quality during storage periods or not. Stability tests are used to 
find out the best formulation the series of formulation. It can be studied by 
applying a stress to the formulation such as temperature, humidity and light. 
Here stability study was conducted for RxSo6 at 40 oC/75% RH 
Label Claim: 
Each 5 ml contains 
Roxithromycin oral suspension 50 mg 
Batch No: RxS06 
Packing: 50ml Labeled amber coloured bottle  
Storage condition: 40 oC ± 2 oC / RH: 75% ± 5% 
 
 
 
 
 
 
Table No.20 
Test Specifications Initial 
observation
After 1 
month 
After 2 
month 
Appearance Orange coloured, 
pleasantly 
flavoured 
suspension with 
sweet taste 
Confirms Confirms Confirms 
Weight/ml 1.2 ±  0.2 1.22 1.22 1.22 
pH 4 to 5 4.51 4.56 4.55 
Assay each 5 ml 
contains 
Roxithromycin 
90.0% -110% 94.47 94.41 94.35 
 
6.1.9 Microbial Evaluation of the optimized formulation RxS06:- 
The microbial; limit test was carried out as per the procedure given section 
5.5.10.  
The observation of formulation RxS06 complies with the specification.  
Since E.coli causes severe dysentery in patients, the absence of the organism in 
RxS06 claim the formulation was made under controlled conditions. 
The result after the incubation time was illustrated in table No.21 
The plate counts for TBC and TFC were depicted in figure. 
 
 
The specific test for E.coli was depicted in Figure no.1 
 
Table No.21 
S.No. Test Specification RxS06 Comment
1 TBC NMT < 100 
CFU 
< 10 CFU complies 
2 TFC NMT < 100 
CFU 
< 10 CFU complies 
3 E.Coli Negative Negative complies 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
The objective of the present study was to develop a stable taste masked 
roxithromycin oral suspension, which could be palatable for infants and 
children. Various batches were developed, Among that  formulations (Rxso1 to 
Rxso6) evaluated and discussed. Formulation Rxso6 was found to be having the 
desirable features of stable suspension such as sedimentation volume, PH, 
viscosity, assay, microbial limit test. Also when subjected under accelerated 
condition the suspension behavior was not altered always. 
Hence it can be concluded that the bitter taste might be masked through 
the efficient drug-resin complex,(Roxithromycin-Indion 204)which was the key 
factor for taste masking. 
             Further evaluation on taste masking for the formulation Rxs06 shall be 
studied in future with human volunteer after obtaining ethical committee 
permission . 
        From all favorable result it was revealed that formulation Rxs06 can be 
concluded as the optimized and stable Roxithromycin oral suspension and 
above evaluation parameter it indicates that the RXS06 are better than the other 
formulations and also from microbial study it        was confirmed that the final 
formulation(RXS06) also protected from microbial growth hence it is good 
suspension for administration. 
 
